December 2024

Phage Display Antibody Discovery

2024-12-20T14:38:21-05:00December 19th, 2024|Articles|

Written by: Jenna Kerry, MSc Published: December 20, 2024 Contents What is Phage Display? How Does Phage Display Work? Phage Display Technology Advantages Phage Display Technology Limitations The Future of Phage Display Technology Overcoming Limitations of Phage Display Antibody Discovery What is Phage Display? Over [...]

B Cells and Their Antibodies

2024-12-10T10:11:07-05:00December 9th, 2024|Articles|

Written by: Genya Gorshtein, MSc Published: December 12, 2024 Contents Introduction B Cells and Their Receptors Antibodies in Serum How Do You Discover Antibodies From Serum? Introduction While B cells play a crucial role in recognizing antigens and initiating immune responses, their differentiation into [...]

B Cell Sequencing and Polyclonal Sequencing Explained

2024-12-09T17:57:13-05:00December 9th, 2024|Articles|

Written by: Genya Gorshtein, MSc Published: December 12, 2024 Contents Introduction BCR and Single B Cell Sequencing for Antibody Discovery Antibody Discovery through De Novo Sequencing of Serum Antibodies Proteogenomics: A Complimentary Approach Antibody Discovery With Rapid Novor Introduction B cell sequencing has long [...]

November 2024

Antibody Humanization Strategies, Challenges, and Innovations

2024-12-11T10:12:25-05:00November 6th, 2024|Articles|

Written by: Jenna Kerry, MSc Published: November 6, 2024 Contents Why Humanize Antibodies? What is Antibody Humanization? Antibody Humanization Techniques Current Challenges of Antibody Humanization The Future of Human Antibody Therapeutics Fully Human Antibody Discovery / Human Antibody Discovery From Human Serum Why Humanize Antibodies? [...]

October 2024

September 2024

Agonist Antibody Challenges and Optimization

2024-10-01T17:08:33-04:00September 18th, 2024|Articles|

Written by: Jenna Kerry, MSc Published: September 17, 2024 Contents Introduction Agonistic Antibody Mechanism of Action Agonistic Antibody Development Challenges Optimizing Agonistic Antibodies Agonistic Antibody Development Introduction In the last decade, immunotherapy has rapidly transformed treatments for cancer, autoimmune disorders, and infectious diseases. While the [...]

August 2024

Best Hosts for Antibody Discovery and Generation

2024-12-03T14:47:53-05:00August 23rd, 2024|Articles|

Written by: Genya Gorshtein, MSc Published: August 26, 2024 Contents Introduction Advantages of Antibody Discovery In Diverse Species Unique Features of Antibodies from Diverse Hosts Antibody Discovery Platforms for Diverse Hosts Introduction The historical use of mice for monoclonal antibody generation has been driven [...]

Antagonistic Antibodies: Opportunities and Obstacles

2024-12-02T13:27:16-05:00August 14th, 2024|Articles|

Written by: Jenna Kerry, MSc Published: August 14, 2024 Contents What are Antagonistic Antibodies? How do Antagonistic Antibodies Work? Antagonistic Antibody Opportunities Antagonistic Antibody Obstacles Antibody Discovery Platform for Antagonistic Antibodies What are Antagonistic Antibodies? Antagonistic antibodies are a monoclonal antibody that bind to and [...]

Interview with Dr. Thierry Le Bihan, Principal Scientist in Polyclonal Antibody Sequencing

2024-12-02T13:42:20-05:00August 1st, 2024|Articles|

Principal Scientist in Polyclonal Antibody Sequencing Dr. Thierry Le Bihan joined Rapid Novor as a Principal Scientist in 2018, tasked with leading a multidisciplinary team to develop a polyclonal antibody sequencing platform. Thierry brought extensive proteomics and mass spectrometry expertise from his previous roles as Director of Proteomics at The Campbell Family Institute [...]

July 2024

Antibody Discovery in Humans – Starting with Functional, Circulating Antibodies

2024-12-03T12:38:28-05:00July 23rd, 2024|Webinars|

This paper is now published in Nature Communications! Le Bihan, T., Nunez de Villavicencio Diaz, T., Reitzel, C. et al. De novo protein sequencing of antibodies for identification of neutralizing antibodies in human plasma post SARS-CoV-2 vaccination. Nat Commun 15, 8790 (2024). https://doi.org/10.1038/s41467-024-53105-8 In this webinar, you will: Explore how using a [...]

Antibody Discovery Processes

2024-12-03T13:51:44-05:00July 3rd, 2024|Articles|

Written by: Vanessa Yoon Calvelo, PhD Published: June 6, 2023 Updated: July 7, 2024 Contents Introduction Early Discovery and Development of Therapeutic Antibodies Target Identification and Validation Antibody Discovery and Expression Lead Characterization and Selection Lead Engineering and Optimization Candidate Selection and Downstream Characterization Introduction [...]

June 2024

Integrating AI and HDX-MS for Antibody Epitope Mapping

2024-08-07T11:52:24-04:00June 5th, 2024|Webinars|

In this webinar, you will learn: How AI and HDX-MS are applied in screening, epitope mapping, and selecting neutralizing antibodies against SARS-Cov-2. The predictive capabilities of AI computational modeling and its validation and refinement by high-resolution HDX-MS. How the integration of AI with HDX-MS informs antibody characterization for the accelerated development of therapeutic [...]

April 2024

November 2023

Alpaca Antibody Discovery and Characterization with Polyclonal Sequencing, SPR and HDX-MS

2024-12-03T14:07:09-05:00November 13th, 2023|Case Studies|

Authors:  Teresa Nunez, Amber Couzens, Jin Duan, Chelsea Reitzel, Rosalin Dubois,  Lin Wu, Qixin Liu, Thierry Le Bihan, Marko Jović, Dominic Narang, Bin Ma  Published: Nov 13, 2023 Abstract In this study, the challenge of accessing functional antibodies from the circulating antibody repertoire was addressed using Rapid Novor's antibody [...]

October 2023

July 2023

Antibody Discovery Dead Ends and New Approaches

2024-12-03T12:39:28-05:00July 20th, 2023|Webinars|

In this webinar, you will learn: About the challenges commonly encountered in antibody discovery campaigns, including non-functional antibodies, limited diversity, developability issues, and immunogenicity. How to de-risk antibody discovery campaigns, while balancing speed and spend Discover how a proteomics and mass spectrometry-based approach to antibody discovery, utilizing REpAb polyclonal sequencing, presents [...]

April 2023

December 2022

Antibody Discovery Platforms

2024-12-03T13:49:44-05:00December 23rd, 2022|Articles|

The great debate on the use of in vivo versus in vitro sources and strategies for antibody discovery and generation continues to thrive among antibody research groups. On one side of the debate is the argument for non-animal-derived antibodies due to the technical advancements of current in vitro technologies, and the moral obligation to reduce animal usage. On the other side of the debate is the counterargument for animal-derived antibodies due to their better performance in affinity, specificity, and reduced immunogenicity risk.

October 2022

July 2022

Adeno-Associated Virus Vectors for Gene Therapy Delivery

2024-12-03T10:41:17-05:00July 14th, 2022|Articles|

Written by: Vanessa Yoon Calvelo, PhD Published: July 11, 2022 Contents What is Gene Therapy? What are Adeno-Associated Viruses? Engineering of AAVs for Gene Therapy Engineering AAVs for Improved Transduction Engineering AAVs for Improved Immunogenicity De Novo Protein Sequencing Applications in AAV Characterization and Development What is Gene [...]

June 2022

Chimeric Antigen Receptors and T cells – CAR-T

2024-12-03T10:43:11-05:00June 21st, 2022|Articles|

Written by: Vanessa Yoon Calvelo, PhD Published: June 13, 2022 Contents What is CAR-T Cell Therapy? CAR Structure and Function CAR-T Cell Development Engineering Strategies for CAR-T Cells De Novo Protein Sequencing Applications in CAR-T Cell Development What is CAR-T Cell Therapy? The infusion of T cells [...]

What is Polyclonal Antibody Sequencing?

2024-12-03T11:00:04-05:00June 1st, 2022|Articles|

The most straightforward solution would be to determine sequences of the dominating antibody forms in a polyclonal mixture to enable recombinant antibody generation and ensure reproducibility. This was recently made possible by the development of polyclonal antibody sequencing technology, which will be reviewed in this article.

April 2022

Broadly Neutralizing Antibody Cocktails Targeting Nipah Virus and Hendra Virus Fusion Glycoproteins

2024-04-24T10:43:58-04:00April 29th, 2022|Case Studies|

Hendra virus (HeV) and Nipah virus (NiV) are types of Henipaviruses (HNVs) that originated in bats and can infect the human respiratory system with detrimental consequences. As enveloped, single-stranded RNA viruses, HeV and NiV use attachment (G) and fusion (F) glycoproteins on the envelope membrane to enter host cells. So far, there are no approved therapeutics or vaccines to combat the viruses in humans.

March 2022

First Immunoassay for Measuring Isoaspartate in Human Serum Albumin

2024-04-24T10:57:11-04:00March 25th, 2022|Case Studies|

The ongoing pandemic has reinforced the need for in vitro diagnostics to globally surveille emerging pathogens and provide better medical care. In particular, immunoassays are favoured due to their affordability, ease, and speed. Nevertheless, the combination of rapidly evolving pathogens, and more complex diseases resulting from increasing life expectancy worldwide require more sensitive and specific immunoassays in the nick of time. To increase sensitivity, immunoassay development can benefit from exploiting industry-leading technologies such as de novo protein sequencing.

February 2022

Camelid Antibodies and Nanobodies

2024-12-03T10:58:32-05:00February 4th, 2022|Articles|

Written by: Yuning Wang, PhD Updated: January 18, 2023 (Published: January 21, 2022) Contents Discovery of Camelid Antibodies What are Camelid Antibodies? Structure of Camelid Antibodies and Nanobodies Advantages of Camelid Antibodies and Nanobodies Camelid Antibodies and Nanobodies for Therapeutic and Research Applications How are Camelid Antibodies [...]

December 2021

Polyclonal Antibody Sequencing in Therapeutics Development Pipelines

2024-04-25T10:13:31-04:00December 20th, 2021|Webinars|

Over the past several years Rapid Novor has been developing the world's best antibody protein sequencing platform, with over 2700 monoclonal antibodies and proteins sequenced. In 2020, they unveiled their most advanced technology to date- REpAb® polyclonal antibody sequencing. The platform combines the world's best protein sequencing technology and NGS to comprehensively mine the antigen specific antibody repertoire present in rabbit and human patient samples. By leveraging the platform, teams can build robust antibody assays and therapeutic leads derived from patient's blood.

Next Generation Protein Sequencing in Veterinary Medicine and Industry

2024-04-24T10:44:32-04:00December 3rd, 2021|Whitepapers|

Since 2006, the One Health Initiative (OHI)’s goal has been to demonstrate the inextricable link between humans, animals, and the environment. Certainly, the current global pandemic is a great testament to the ties between climate change, humans, and animals that OHI has been working to highlight. The rise of other zoonotic diseases (e.g., Hendra, and Nipah viruses) not only directly affect humans through disease transmission but may also result in deep impacts to the food supply

October 2021

Ushering the New Era in Anti-Drug Antibody Assays with Next Generation Protein Sequencing

2024-04-24T10:45:13-04:00October 15th, 2021|Whitepapers|

Anti-drug antibody (ADA) assays are critical to assess the clinical efficacy and safety of a biological drug and rely on control reagents that mimic the ADA response to the biological drug being tested. These positive controls typically consist of animal-derived pooled polyclonal antibodies or human monoclonal antibody reference panels against the target protein drug.

September 2021

Monoclonal vs Polyclonal Antibody Drugs

2024-12-03T11:21:15-05:00September 8th, 2021|Articles|

The transition from polyclonal antibody drugs to a more targeted monoclonal approach was made possible through a series of scientific and technological advancements; the most notable of which is the hybridoma technique developed by Köhler and Milstein, which allowed the generation of pure antibodies at scale.

July 2021

May 2021

Polyclonal Antibody Sequencing with Only Proteomics

2024-04-25T10:12:57-04:00May 13th, 2021|Webinars|

Over the past 5 years Rapid Novor has perfected monoclonal antibody sequencing, and is now sequencing mAbs from polyclonal mixtures using REpAb®.  After successfully launching their proteogenomics based sequencing technology to deconvolute the immune response, the team has further evolved the technology and has derived the most abundant mAb sequences directly from rabbit blood using only proteomics. The talk will surround the development, progress and use cases for REpAb®.

April 2021

Leveraging pAbs for Therapeutic Development

2024-12-03T12:47:40-05:00April 13th, 2021|Webinars|

Over the past several years Rapid Novor has been developing the world’s best antibody protein sequencing platform, sequencing over 2700 monoclonal antibodies and proteins. In 2020, they unveiled their most advanced technology to date - REpAb® polyclonal antibody sequencing. The platform combines the world’s best protein sequencing technology and NGS to comprehensively mine the antigen-specific antibody repertoire present in rabbit and human patient samples. By leveraging the platform, teams can build robust antibody assays and therapeutic leads derived from patients’ blood.

March 2021

June 2016

Moving Towards Recombinant Monoclonal Antibodies

2023-05-15T11:59:37-04:00June 30th, 2016|Articles|

Recombinant Monoclonal Antibodies (rAbs) are highly reproducible, customizable and pure alternatives to the traditional antibodies produced by hybridomas. Get the antibody protein sequence, either by DNA sequencing or the de novo protein sequencing technology, you can rest assured that you can have the exact antibody made recombinantly anytime in the future.